Home
    Disclaimer
    Methoxphenidine molecular structure

    Methoxphenidine Stats & Data

    Mxp 2-mxp Methoxyphenidine 2-meo-diphenidine
    NPS DataHub
    MW295.42
    FormulaC20H25NO
    CAS127529-46-8
    IUPAC1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine
    SMILESCOc1ccccc1C(Cc1ccccc1)N1CCCCC1
    InChIKeyQXXCUXIRBHSITD-UHFFFAOYSA-N
    Phenethylamines; Others; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Psychoactive Class Dissociative
    Half-Life Unknown in humans; clinical intoxication cases report prolonged effects, especially with high doses or polydrug use.

    Subjective Effects

    Physical
    • Tactile disconnection: This results in typical states of progressive physical disconnection but is far more consciously controllable than that of other dissociatives. This allows one to choose how much of their body they are currently aware of and connected to simply by directing their focus towards it.
    • Spontaneous tactile sensations: The MXP body high is a soft, pleasurable vibrating sensation. It can be felt all over the body and progressively intensifies throughout the onset before dissipating once the peak has been reached.
    • Tactile suppression: This partially to entirely suppresses one's sense of touch, creating feelings of numbness within the extremities. It is responsible for the anaesthetic properties of this substance.
    • Physical autonomy
    • Motor control loss: A loss of gross and fine motor control alongside of balance and coordination is prevalent within MXP and becomes especially strong at higher dosages.
    • Physical euphoria: This results in feelings of physical euphoria which range between mild pleasure to powerful all-encompassing bliss.
    • Decreased bodily weight: This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate dosages.
    • Dizziness
    Cognitive
    • Consciousness disconnection
    • Acceleration of thought
    • Ego suppression, loss and death
    • Time distortion: Feelings of time dilation and more time having passed than it actually has are common at moderate to strong dosages.
    • Euphoria
    • Conceptual thinking
    Sensory
    Auditory
    • Enhancements
    Visual · Hallucinatory States
    • Visual disconnection: This eventually results in the MXP equivalent of the K-hole, consisting of holes, spaces and voids alongside of structures.
    • Internal hallucinations: (Autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - These hallucinatory states can be described as dream like in nature. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, mostly unimmersive in style and extremely controllable in their content in a way which allows one to choose what they wish to see.

    Forked from Subjective Effect Documentation by Josie Kins, March 2014. Via dose.wiki (CC0).

    Effect Profile

    Curated + 30 Reports
    Dissociative 6.0

    Strong dissociative depth, mania, and motor impairment with moderate insight

    Dissociative Depth×3
    1010
    Mania / Compulsion×1
    105.4
    Insight / Novel Thought×2
    6
    Motor / Sensory Impairment×1
    104.2
    Catalog Erowid

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    30 minutes - 2.0 hours
    30 minutes - 1.0 hours
    2-5 hours
    2-3 hours
    6-24 hours
    Total: 6-8 hours
    Insufflated
    10-45 minutes
    15-30 minutes
    2-4 hours
    1-2 hours
    6-24 hours
    Total: 6-8 hours
    Intravenous
    30 minutes - 1.0 hours
    2-3 hours
    1-2 hours
    6-12 hours
    Total: 6-8 hours

    Community Effects

    TripSit
    Positive
    energy dissociation
    Negative
    mania amnesia addiction

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; clinical intoxication cases report prolonged effects, especially with high doses or polydrug use.
    Addiction Potential
    Moderate; psychological dependence with compulsive redosing is reported among dissociatives.

    Tolerance Decay

    Full tolerance 2d Half tolerance 7d Baseline ~21d

    Rapid tolerance build is commonly reported with frequent dissociative use; decay back to baseline typically requires weeks. Values are heuristic aggregates from user reports across dissociatives; specific MXP kinetics are poorly characterized. Avoid consecutive-day use to limit escalation and compulsive redosing.

    Cross-Tolerances

    Ketamine
    50% ●○○
    DXM
    40% ●○○
    3-MeO-PCP and related arylcyclohexylamines
    60% ●○○

    Experience Report Analysis

    Erowid
    30 Reports
    2013–2022 Date Range
    29 With Age Data
    26 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 30 experience reports (30 Erowid)

    30 Reports
    26 Effects Detected
    9 Positive
    8 Adverse
    9 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 9

    Music Enhancement 56.7% 70%
    Empathy 46.7% 70%
    Euphoria 40.0% 70%
    Stimulation 40.0% 70%
    Focus Enhancement 33.3% 70%
    Tactile Enhancement 33.3% 70%
    Introspection 30.0% 70%
    Color Enhancement 26.7% 70%
    Body High 26.7% 70%

    Adverse Effects 8

    Anxiety 56.7% 70%
    Confusion 36.7% 70%
    Memory Suppression 23.3% 70%
    Increased Heart Rate 13.3% 70%
    Headache 13.3% 70%
    Nausea 13.3% 70%
    Motor Impairment 10.0% 70%
    Psychosis 10.0% 70%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 100.0 mg IQR: 80.0–150.0 mg n=16

    Real-World Dose Distribution

    62K Doses

    From 49 individual dose entries

    Oral (n=31)

    Median: 85.0mg 25th: 45.0mg 75th: 100.0mg 90th: 150.0mg
    mg/kg median: 1.16 mg/kg 75th: 1.667

    Insufflated (n=10)

    Median: 50.0mg 25th: 30.0mg 75th: 50.0mg 90th: 53.0mg
    mg/kg median: 0.682 mg/kg 75th: 0.848

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 1.471 mg/kg IQR: 1.16–1.897 mg/kg n=15

    Redose Patterns

    Redosing behavior across 25 reports

    44.0% Redosed
    1.8 Avg Doses
    50m Median Interval

    Harm Reduction

    drugs.wiki

    MXP is a diarylethylamine dissociative (diphenidine family), not an arylcyclohexylamine; conflating it with ketamine-like arylcyclohexylamines can mislead dosing expectations and risk assessment. Its effects can be slower to build than expected, making early redoses risky due to delayed peaks; many cases of over-intoxication follow stacking doses too closely. Several medical reports describe prolonged agitation, confusion, and need for sedation after high doses or polydrug use, underscoring its unpredictability compared with ketamine. Combining MXP with CNS depressants (alcohol, opioids, GHB/GBL, sedatives) markedly increases risk of blackouts, aspiration, accidents, and respiratory complications even if dissociatives alone are not strong respiratory depressants. Stimulant combinations can worsen cardiovascular strain and agitation; serotonergic antidepressants (SSRIs/SNRIs/MAOIs) may interact unpredictably because the diarylethylamine class has had mixed and incompletely characterized monoaminergic activity signals—err on the side of avoiding. Tolerance to dissociatives can build quickly with repeated use and shows cross-tolerance within the class, which tempts dose escalation and elevates harm. Chronic heavy dissociative use (well-documented with ketamine) is linked to urinary tract symptoms; specific MXP data are sparse, so prudent spacing and hydration are advisable to reduce potential urological stress. Because supply is unregulated, mislabeling and unexpected adulterants are common; using a reputable drug checking service (or at minimum reagent tests) before consumption reduces the risk of consuming the wrong drug or a dangerously potent adulterant. Non-medical IV use greatly elevates risk (unknown excipients, microbial contamination, local tissue injury, dosing overshoot); if someone nevertheless intends to inject, single-substance use, sterile technique, and micron filtration reduce but do not remove these risks. Strong set and setting effects are reported: high or chaotic doses can precipitate paranoia, delusions, or unsafe behavior; a sober sitter, safe environment, and avoiding hazards (roads, water, heights) meaningfully reduce accident risk. Accurate milligram measurement with a calibrated scale and volumetric dosing practices reduce accidental overdosing when working with variable-potency RC powders. Space sessions by at least 2–4 weeks to manage tolerance and reduce compulsive redosing patterns; consider pre-planning a cap on total session dose.

    ← Back to Methoxphenidine